By Rahul Koul
“ Biopharma industry has seen strategic advancements in terms of technology enhancement ”
Dr Sanjib Banerjee , Chief Operating Officer ( Biopharma Division ), Veeda Clinical Research Limited explains the latest industry trends and initiatives by his company
By Rahul Koul
Tell us more about the Biopharma Division at Veeda Clinical Research ? How have you further strengthened the capabilities at Bengaluru facility ?
Veeda Clinical Research Limited together with its subsidiary , Bioneeds India Private Limited , referred as the “ Veeda Group ”, offers a comprehensive portfolio of drug discovery and development services to support innovator , NCEs , NBEs , biosimilar and generic drug development programs of global clientele .
In an industry where innovation is increasingly multifaceted and collaborative , Veeda aspires to be the research partner of choice for innovative pharmaceutical and biopharmaceutical companies worldwide for their critical product development programs .
With increasing regulatory focus on evaluating the totality of evidence for similarbiologics and biological products that combines non-clinical and clinical assessments , Veeda Clinical Research believes that having an amalgamation of all the biopharma services including discovery , analytical , pre-clinical / clinical bioanalyticaland clinical services will be of competitive advantage both in building integratedexpertise as well as for providing comprehensive servicing to the clients . Veeda ’ s management team
BioTech
BIOVOICENEWS . COM 51